Nyra Medical, a spinout of Emory University, is developing a novel device to treat mitral regurgitation (MR), a severe heart condition in which the mitral valve between the left atrium and left ventricle does not seal properly, resulting in leakage of blood backward through the mitral valve each time the left ventricle contracts. MR can lead to enlargement of the atrium and ventricle, abnormal heart rhythms, pulmonary hypertension, and heart failure. Nyra’s cardiac leaflet enhancer (CARLEN) is a first-in-class device delivered percutaneously to correct MR while preserving the physiological valve geometry.
Go to website: https://www.nyramed.com/news.html